Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

June 1, 2023

Study Completion Date

March 5, 2024

Conditions

Ovarian Cancer Stage IVPeritoneal CancerFallopian Tube Cancer

Interventions

DRUG

Carboplatin

Carboplatin AUC=6

DRUG

Paclitaxel

paclitaxel 80 mg/m2

DRUG

Pembrolizumab

200 mg flat dose, starting cycle 2

Trial Locations (1)

Antoni van Leeuwenhoek, Amsterdam

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03126812 - Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | Biotech Hunter | Biotech Hunter